Al Gore on Impeachment, Adam Silver on China and Selma Blair on Her MS Diagnosis: Here Are Biggest Moments From the TIME 100 Health Summit
TIME held its first TIME 100 Health Summit on Thursday aiming to define — and shape — the future of health care. The Summit, which is an offshoot of the magazine’s annual TIME 100 list of influential people, featured scientists, politicians and entertainers, such as former President Bill Clinton, former Vice President Al Gore, NIH Director Dr. Francis Collins, actress Selma Blair, NBA commissioner Adam Silver, comedian Tig Notaro and former Planned Parenthood President Dr. Leana Wen. The day included a range of interviews, panels and performances. Here are the biggest moments from the Summit. Former Vice President Al Gore told Nancy Gibbs it’s not impossible for the Senate to vote to convict and remove the President Former Vice President Al Gore told former TIME Editor-in-Chief Nancy Gibbs that it’s possible the House of Representatives could impeach President Donald Trump and the Senate could vote to convict and remove him from office. “It’s probably still unlikely the Republican Senate would convict, but I don’t think it’s any longer possible to say that’s a certainty by any means,” he said. “Of course most people have assumed that the Republican controlled Senate would never convict and remove. I don’t know, the evidence still matters.” Gore also urged Americans to vote out politicians in both parties who oppose policies meant to combat climate crisis. “If you care about this climat...
Authors: Reissier S, Cattoir V Abstract INTRODUCTION: Streptogramins (pristinamycin and quinupristin-dalfopristin) can be interesting options for the treatment of infections due to Gram-positive cocci, especially multidrug-resistant isolates. AREAS COVERED: This review provides an updated overview on structural and activity characteristics, mechanisms of action and resistance, pharmacokinetic/pharmacodynamic and clinical use of streptogramins. EXPERT OPINION: The streptogramin antibiotics act by inhibition of the bacterial protein synthesis. They are composed of two chemically distinct compounds, namely typ...
Publication date: 15 February 2021Source: Journal of Hazardous Materials, Volume 404, Part BAuthor(s): Yanhua Liu, Yang Li, Shanshan Dong, Lu Han, Ruixin Guo, Yourong Fu, Shenghu Zhang, Jianqiu Chen
Publication date: 15 February 2021Source: Journal of Hazardous Materials, Volume 404, Part AAuthor(s): Zhongyi Zhang, Wen-Xiong Wang, Nengjian Zheng, Yansheng Cao, Hongwei Xiao, Renguo Zhu, Hui Guan, Huayun Xiao
Publication date: Available online 9 October 2020Source: Journal of Hazardous MaterialsAuthor(s): Yubo Cheng, Yiqiu Ma, Biao Dong, Xinghua Qiu, Di Hu
We describe the most highly recommended generic and disease-specific PRO tools in SCD and discuss the challenges of incorporating them in clinical practice. EXPERT OPINION: PRO measures are essential to incorporate into SCD clinical trials either as primary or secondary outcomes. The use of PRO measures in SCD facilitates a patient-centered approach, which is likely to lead to improved outcomes. Significant challenges remain in adapting PRO tools to routine clinical use and in developing countries. PMID: 33034214 [PubMed - as supplied by publisher]
Authors: Musio F Abstract INTRODUCTION: Anemia has and will continue to be a central theme in medicine particularly as clinicians are treating a burgeoning population of complex multi-organ system processes. As a result of multiple randomized controlled trials (RCTs), meta-analyses, and societal recommendations overly restrictive paradigms and under-administration of erythropoiesis stimulating agents (ESAs) have likely been followed by clinicians among all specialties. AREAS COVERED: A review of anemia in the context of chronic kidney disease, hematologic malignancies and cancer is presented with focus on the e...
Publication date: Available online 10 October 2020Source: Meta GeneAuthor(s): Mansour Zamanpoor, Hamid Ghaedi, Mir Davood Omrani
Publication date: January 2021Source: Urology Case Reports, Volume 34Author(s): Nina Al-Saadi, Safa Al-Musawi, Yousuf Khan, Daben Dawam
Currently in fellowship doing bread/butter procedures (MBB, epidurals, PNB, few SCS/PNS trials, etc.) and just interviewed at a private practice spot where they do a lot of procedures that I will have not done any training in prior to graduating (e.g. IT pump, SI fusion, Vertiflex, Kypho, MILD, Discectomy, lots of SCS/PNS trials etc) and significant amount of "OR pain procedures" at a very busy practice seeing 30-40 pts/day - how many of you are commonly performing these procedures and are... private practice concern
Authors: Matti B, Zargar-Shoshtari K Abstract Prostate cancer represents a significant health burden worldwide. The cancer incidence had substantially increased since the introduction of prostate specific antigen (PSA) in cancer screening. This had led to considerable debates among health professionals and epidemiologists, since PSA as a screening tool seemed to be far from perfect. In New Zealand, the controversy was quite prominent in the last three decades, with some advocating the benefits of screening, while others concerned regarding the risk of harms. With the absence of an organised screening programme and ...
More News: Acupuncture | Addiction | Alzheimer's | American Health | Arthritis | Atrial Fibrillation | Back Pain | Breast Cancer | Burns | Cancer | Cancer & Oncology | Centers for Medicare and Medicaid Services (CMS) | China Health | Chronic Pain | Department of Health | Education | Endemics | France Health | Fruit | Genetics | Girls | Government | Harvard | Health | Health Management | Hong Kong Health | Immunotherapy | International Medicine & Public Health | Internet | Legislation | Mastectomy | Medicaid | Medicare | Men | Midwifery | Multiple Sclerosis | Nurses | Nursing | Pain | Partnerships | Pfizer | Politics | Rheumatology | Salaries | Science | Sports Medicine | Trump | USA Health | Washington University | Women